Jul 26, 2012 by Brian Orelli, PhDBesides That Bristol, How Was the Show?Bristol-Myers looks just fine post-Plavix.
Jul 25, 2012 by Brian Orelli, PhDWill the FDA Approve Amarin's AMR101?An approval is as likely as you can get with the FDA.
Jul 25, 2012 by Brian Orelli, PhDWhat's in Store for Biotech Investors in the Second Half of 2012 Looking back at the year in biotech and what stocks to watch going forward.
Jul 24, 2012 by Brian Orelli, PhDDon't Forget: Alzheimer's Drug Development Is GamblingBapineuzumab fails for now.
Jul 23, 2012 by Brian Orelli, PhDFDA Approval and a Trial Failure: Which Is More Important?Onyx Pharmaceuticals announces both in successive business days.
Jul 21, 2012 by Brian Orelli, PhDDouble Disappointment! Has This Pharma Lost Its Touch?Bristol-Myers Squibb's brivanib fails to treat liver cancer. Again.
Jul 21, 2012 by Brian Orelli, PhDA Buying Opportunity for a 3-Year TripleIntuitive Surgical hits a bump but should keep on going.
Jul 18, 2012 by Brian Orelli, PhDA Useful Drug That Few Will TakeGilead gains FDA approval for Truvada as a prophylactic.
Jul 18, 2012 by Brian Orelli, PhDLowered Guidance? No Problem for This Dividend Dynamo.Currency fluctuations can be ignored.
Jul 16, 2012 by Brian Orelli, PhDIs a VIVUS Win Arena's Loss?Market will grow faster with two drugs being promoted.
Jul 16, 2012 by Brian Orelli, PhDNo White Knight RequiredHuman Genome gets taken out by GlaxoSmithKline.
Jul 14, 2012 by Brian Orelli, PhDWill the FDA Approve VIVUS' Obesity Drug?All signs point to yes, but the FDA restrictions will be important for commercial success.
Jul 14, 2012 by Brian Orelli, PhD3 Reasons to Buy Spectrum PharmaceuticalsA specialty pharma to consider.
Jul 13, 2012 by Brian Orelli, PhDCelgene's Treading Into Open WaterAnti-inflammatory apremilast looks promising, but will have competition.
Jul 13, 2012 by Brian Orelli, PhDCan Eli Lilly Save This Drug?Eli Lilly's pomaglumetad methionil fails, but the company still seems to have faith.
Jul 12, 2012 by Brian Orelli, PhDPotential, No Bones About ItMerck's osteoporosis drug has potential, but there's not enough data to know how much.
Jul 11, 2012 by Brian Orelli, PhDCan These 3 Companies Take Down Gilead?Dolutegravir proves superior to Gilead's Atripla.
